Calcitonin Gene–Related Peptide Monoclonal Antibody Versus Botulinum Toxin for the Preventive Treatment of Chronic Migraine: Evidence From Indirect Treatment Comparison

Background: The previously approved botulinum toxin and nowadays promising calcitonin gene-related peptide (CGRP) monoclonal antibody have shown efficacy for preventing chronic migraine (CM). However, there is no direct evidence for their relative effectiveness and safety. In this study, we conducte...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Front Pharmacol
Main Authors: Lu, Jiajie, Zhang, Quanquan, Guo, Xiaoning, Liu, Wei, Xu, Chunyang, Hu, Xiaowei, Ni, Jianqiang, Lu, Haifeng, Zhao, Hongru
Formato: Artigo
Idioma:Inglês
Publicado em: Frontiers Media S.A. 2021
Assuntos:
Pharmacology
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC8126691/
https://ncbi.nlm.nih.gov/pubmed/34012392
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fphar.2021.631204
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados